Status:
UNKNOWN
The Resistance and Immune Response to Palbociclib in Breast Cancer
Lead Sponsor:
Samsung Medical Center
Conditions:
Breast Cancer Stage IV
Eligibility:
FEMALE
Phase:
NA
Brief Summary
The investigators propose to conduct a biomarker and molecular profiling study in longitudinally paired tumor biopsies and serum from patients with Hormone Receptor positive (HR+) metastatic Breast Ca...
Detailed Description
The investigators propose to conduct a biomarker and molecular profiling study in longitudinally paired tumor biopsies and serum from patients with Hormone Receptor positive (HR+) metastatic Breast Ca...
Eligibility Criteria
Inclusion
- Hormone receptor positive, metastatic breast cancer
- Treated by palbociclib with endocrine therapy
Exclusion
- Hormone receptor negative breast cancer
- Treated without palbociclib
- Refuse and withdrawal to this study
Key Trial Info
Start Date :
October 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03401359
Start Date
October 24 2017
End Date
October 31 2022
Last Update
January 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351